IMR Press / FBS / Volume 3 / Issue 1 / DOI: 10.2741/S128

Frontiers in Bioscience-Scholar (FBS) is published by IMR Press from Volume 13 Issue 1 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Targeting EGFR in bilio-pancreatic and liver carcinoma
Show Less
1 Medical Oncology, University Campus Bio-Medico, Rome
2 Medical and Experimental Oncology Unit, Scientific Institute for Research and Treatment of Cancer “Giovanni Paolo II”, Bari
3 Clinical Experimental Oncology Laboratory, Scientific Institute for Research and Treatment of Cancer “Giovanni Paolo II”
4 Medical Oncology Unit, Scientific Institute for Research and Treatment of Cancer “Casa Sollievo della Sofferenza” – San Giovanni Rotondo

*Author to whom correspondence should be addressed.

Academic Editor: Amalia Azzariti

Front. Biosci. (Schol Ed) 2011, 3(1), 16–22;
Published: 1 January 2011

The key role of epidermal growth factor receptor(EGFR) in tumorigenesis has been demonstrated in several cancer types, so recent clinical trials have investigated their activity/efficacy in different settings. Two different types of EGFR-targeted agents were developed: monoclonal antibodies such as cetuximab and panitumumab, and tyrosine kinase inhibitors, such as gefitinib and erlotinib. In this review, we summarize the preclinical rational of potential activity and the most important clinical trials evaluated anti-EGFR targeted agents in non-colorectal digestive cancer, both in monotherapy and in combination with other chemotherapeutic or targeted agents. Patient selection by use of biologic markers will identify which patients are more likely to respond, contributing to the successful use of these agents.

Back to top